Furthermore, incubation of neoantigen peptide #22-stimulated CD8+T cells with MDA-MB-231 in the presence of anti-MHC-I antibodies or with BT549 (HLA-A*02:01-positive/peptide #22-negative) resulted in negligible IFN-γ production (figure 2B) and poor killing activity (figure 2C), showing that the recognition of the tumor cells by the neoantigen peptide #22-stimulated CD8+T cells is HLA-restricted and antigen-specific. The gene discussed is CD8A; the disease is neoplasm.